Plasma Cell Neoplasm – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 0 PAGES: 129

More Info
									        Plasma Cell Neoplasm – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1929IDB
                                                                                              Publication Date: April 2012




Plasma Cell Neoplasm – Pipeline Review, H1 2012                                               GMDHC1929IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Plasma Cell Neoplasm – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 8
Introduction......................................................................................................................................................................................... 9
    Global Markets Direct Report Coverage ........................................................................................................................................ 9
Plasma Cell Neoplasm Overview ..................................................................................................................................................... 10
Therapeutics Development............................................................................................................................................................... 11
    An Overview of Pipeline Products for Plasma Cell Neoplasm ..................................................................................................... 11
Plasma Cell Neoplasm Therapeutics under Investigation by Universities/Institutes ......................................................................... 13
Late Stage Products ......................................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Early Clinical Stage Products ........................................................................................................................................................... 18
    Comparative Analysis .................................................................................................................................................................. 18
Plasma Cell Neoplasm Therapeutics – Products under Investigation by Universities/Institutes ....................................................... 19
Plasma Cell Neoplasm – Therapeutics Assessment ........................................................................................................................ 23
    Assessment by Monotherapy Products ....................................................................................................................................... 23
    Assessment by Combination Products ........................................................................................................................................ 24
    Assessment by Route of Administration ...................................................................................................................................... 25
    Assessment by Molecule Type .................................................................................................................................................... 27
Drug Profiles..................................................................................................................................................................................... 29
    Bortezomib - Drug Profile ............................................................................................................................................................ 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Lenalidomide + Dexamethasone - Drug Profile ........................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Zolinza+ Velcade + Doxil - Drug Profile ....................................................................................................................................... 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 32
    Bryostatin 1 + Vincristine - Drug Profile ....................................................................................................................................... 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    Bevacizumab + Lenalidomide + Dexamethasone - Drug Profile.................................................................................................. 35
         Product Description................................................................................................................................................................. 35
         Mechanism of Action ............................................................................................................................................................... 35
         R&D Progress ......................................................................................................................................................................... 35



Plasma Cell Neoplasm – Pipeline Review, H1 2012                                                                                                    GMDHC1929IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Plasma Cell Neoplasm – Pipeline Review, H1 2012



    Aflibercept - Drug Profile ............................................................................................................................................................. 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Sunitinib Malate - Drug Profile ..................................................................................................................................................... 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Natural Killer Cells - Drug Profile ................................................................................................................................................. 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    CD4 + CD25 + Regulatory T Cells + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile .................................. 39
        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    Velcade + Melphalan + Dexamethasone - Drug Profile ............................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Zoledronic Acid - Drug Profile ...................................................................................................................................................... 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Anakinra - Drug Profile ................................................................................................................................................................ 44
        Product Description................................................................................................................................................................. 44
        Mechanism of Action ............................................................................................................................................................... 44
        R&D Progress ......................................................................................................................................................................... 44
    Cyclophosphamide + Fludarabine + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation +
    Therapeutic Allogeneic Lymphocytes - Drug Profile .................................................................................................................... 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 46
    Revlimid - Drug Profile ................................................................................................................................................................. 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    Anti-Thymocyte Globulin + Cyclophosphamide + Fludarabine + Peripheral Blood Stem Cell Transplantation - Drug Profile...... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Anti-Thymocyte globulin + G-CSF + Cyclophosphamide + Fludarabine + Umbilical Cord Blood Transplantation +
    Methylprednisolone - Drug Profile ............................................................................................................................................... 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51


Plasma Cell Neoplasm – Pipeline Review, H1 2012                                                                                               GMDHC1929IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Plasma Cell Neoplasm – Pipeline Review, H1 2012



        R&D Progress ......................................................................................................................................................................... 52
    G-CSF + Busulfan + Cyclophosphamide + Cyclosporine + Peripheral Stem Cell Transplantation - Drug Profile........................ 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    SU6668 - Drug Profile ................................................................................................................................................................. 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action ............................................................................................................................................................... 54
        R&D Progress ......................................................................................................................................................................... 54
    Fludarabine + Cyclophosphamide + Cyclosporine + Allogeneic Lymphocytes + Peripheral Blood Stem Cell Transplantation +
    Allogeneic Hematopoietic Stem Cell Transplantation + Total Body Irradiation - Drug Profile ...................................................... 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 56
    Anti-Lymphocyte Globulin + Busulfan + Fludarabine + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile ...... 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    Id-KLH Vaccine + GM-CSF - Drug Profile ................................................................................................................................... 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    Dexamethasone + Etoposide + Cisplatin + Cyclophosphamide + Filgrastim - Drug Profile......................................................... 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 61
    Busulfan + Cyclophosphamide + Stem Cell Transplant + Irradiation - Drug Profile..................................................................... 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Cyclophosphamide + Fludarabine Phosphate + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug Profile ....... 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Sargramostim + Therapeutic Allogeneic Lymphocytes + Busulfan + Fludarabine Phosphate + Methotrexate + Tacrolimus +
    Anti-Thymocyte Globulin + Stem Cell Transplantation - Drug Profile .......................................................................................... 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 67
    Melphalan + Holmium-166-DOTMP - Drug Profile ...................................................................................................................... 68
        Product Description................................................................................................................................................................. 68
        Mechanism of Action ............................................................................................................................................................... 68
        R&D Progress ......................................................................................................................................................................... 68
    Velcade + Thalidomide + Dexamethasone - Drug Profile ............................................................................................................ 69
        Product Description................................................................................................................................................................. 69


Plasma Cell Neoplasm – Pipeline Review, H1 2012                                                                                               GMDHC1929IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
Plasma Cell Neoplasm – Pipeline Review, H1 2012



        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Cyclophosphamide + Radiotherapy + Allogeneic Bone Marrow Transplantation + Cyclosporine + Methotrexate - Drug Profile. 71
        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71
    Carmustine + Cyclophosphamide + Etoposide + Autologous Stem Cell Transplantation - Drug Profile...................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile .......................................... 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile .............................................................. 76
        Product Description................................................................................................................................................................. 76
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 76
    Etoposide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile ........................................................................ 77
        Product Description..................................................................................
								
To top